Publikation

Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial.

Wissenschaftlicher Artikel/Review - 20.09.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Boesing M, Abig K, Brändle M, Brutsche M, Burri E, Frye B, Giezendanner S, Grutters J, Haas P, Heisler J, Jaun F, Leuppi-Taegtmeyer A, Lüthi-Corridori G, Müller-Quernheim J, Nüesch R, Pohl W, Rassouli F, Leuppi J. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. Trials 2022; 23:790.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Trials 2022; 23
Veröffentlichungsdatum
20.09.2022
eISSN (Online)
1745-6215
Seiten
790
Kurzbeschreibung/Zielsetzung

Despite the fast establishment of new therapeutic agents in the management of COVID-19 and large-scale vaccination campaigns since the beginning of the SARS-CoV-2 pandemic in early 2020, severe disease courses still represent a threat, especially to patients with risk factors. This indicates the need for alternative strategies to prevent respiratory complications like acute respiratory distress syndrome (ARDS) associated with COVID-19. Aviptadil, a synthetic form of human vasoactive intestinal peptide, might be beneficial for COVID-19 patients at high risk of developing ARDS because of its ability to influence the regulation of exaggerated pro-inflammatory proteins and orchestrate the lung homeostasis. Aviptadil has recently been shown to considerably improve the prognosis of ARDS in COVID-19 when applied intravenously. An inhaled application of aviptadil has the advantages of achieving a higher concentration in the lung tissue, fast onset of activity, avoiding the hepatic first-pass metabolism, and the reduction of adverse effects. The overall objective of this project is to assess the efficacy and safety of inhaled aviptadil in patients hospitalized for COVID-19 at high risk of developing ARDS.